All In Biotech

Drug Trial Radar · NCT05709314

A Study of AMDX-2011P in Participants With CAA

A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Jul 9, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Amydis Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).

Conditions

  • Cerebral Amyloid Angiopathy

Interventions

  • AMDX-2011PDrug

    AMDX-2011P single bolus injection intravenous for diagnostic review

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AMDX-2011P Adverse Events ProfileTime frame: 8 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.